In a significant move to advance surgical innovation, the Chinese Society of Breast Surgery, under the Chinese Society of Surgery and the Chinese Medical Association, has released comprehensive guiding opinions aimed at promoting the standardized, healthy, and scientific development of robotic-assisted breast surgery (RBS) within China. This initiative, detailed in a recent publication, addresses the rapid global and domestic uptake of robotic systems in breast procedures, emphasizing the need for structured training, clear indications, and collaborative research to ensure patient safety and technological efficacy. The guidelines emerge as robotic surgery, particularly in breast oncology and reconstruction, gains traction across Chinese medical centers, with over 1,000 procedures reported domestically by mid-2025. The document underscores China’s commitment to integrating cutting-edge medical robotics into mainstream surgical practice while fostering indigenous innovation in this high-stakes field.
The guiding opinions were formulated by a multidisciplinary panel of experts from the Chinese Society of Breast Surgery, who conducted an extensive review of domestic and international literature. They highlight the transformative potential of robotic-assisted systems, which offer advantages such as tremor elimination, seven degrees of freedom in instrument movement, and high-definition three-dimensional visualization. These features have already revolutionized fields like general surgery, gynecology, urology, and plastic surgery. In China, the adoption of robotic breast surgery is seen as a natural progression from laparoscopic techniques, with the potential to simplify learning curves and enhance surgical precision. The guidelines are supported by several funded programs, including the Jilin Province Key Research and Development Program and projects from the Beijing Kechuang Medical Development Foundation, reflecting strong institutional backing for technological advancement in healthcare.
The release of these guidelines coincides with a period of rapid growth in China’s medical robotics sector, where domestic and international systems are being deployed in operating rooms. The experts stress that while robotic breast surgery in China is still in its early stages, primarily at automation level 1 (robot-assisted), the future holds promise for fully autonomous systems. The guidelines aim to steer this evolution responsibly, ensuring that clinical practices are grounded in evidence and ethical considerations. As China robot technology continues to evolve, these recommendations are expected to serve as a blueprint for other specialties, positioning the country as a leader in the global robotics-in-medicine landscape.
1. The Current Landscape of Robotic Breast Surgery in China and Globally
Robotic-assisted surgery has witnessed exponential growth worldwide since the introduction of the da Vinci surgical system in 2000. To date, over 70 countries have adopted robotic systems, cumulatively performing more than 11 million procedures. In China, robotic breast surgery has emerged as a focal point of innovation, with approximately 20 medical centers reporting experience in RBS by July 2025. These centers have collectively conducted over 1,000 surgeries, primarily for early-stage breast cancer patients. The procedures encompass a wide range, including robot-assisted nipple-sparing mastectomy, immediate breast reconstruction (with autologous tissue or implants), breast-conserving surgery, sentinel lymph node biopsy, axillary lymph node dissection, and internal mammary lymph node dissection. Additionally, applications extend to benign conditions like gynecomastia in male patients.
The appeal of China robot-assisted systems lies in their technical superiority over traditional methods. Robotic platforms provide surgeons with enhanced dexterity, magnified 3D views, and improved ergonomics, which are particularly beneficial in the confined and anatomically complex breast region. These advantages have led to preliminary satisfactory outcomes in local disease control, breast cosmesis preservation, and psychosocial adaptation for patients. However, the experts note that the current evidence base relies heavily on single-center, non-randomized studies, necessitating more robust research to validate long-term efficacy and safety.
A critical framework discussed in the guidelines is the automation grading system for surgical robots, which categorizes technological progression from manual control to full autonomy. This system is pivotal for understanding the trajectory of China robot development in healthcare. The table below outlines the classification levels, as referenced in the guiding opinions:
| Classification Basis | Level/Type | Description |
|---|---|---|
| By Autonomy Level | Level 0: No Autonomy | All operations are fully controlled by the surgeon. |
| Level 1: Robot-Assisted | The surgeon continuously controls the procedure, with the robot providing guidance and assistance. | |
| Level 2: Task Automation | The robot performs specific tasks automatically, but initiation requires human control. | |
| Level 3: Conditional Automation | The robot executes parts of tasks automatically based on selected strategies, with surgeon oversight. | |
| Level 4: High Automation | The robot independently completes tasks according to predefined strategies without intervention. | |
| Level 5: Full Automation | The robot performs the entire surgical procedure autonomously. | |
| By Clinical Application Area | Laparoscopic Robots (Multi-port/Single-port) | Used in minimally invasive abdominal and thoracic surgeries. |
| Orthopedic Robots | Employed in bone-related procedures for precision. | |
| Percutaneous Puncture Robots | Assist in needle-based interventions like biopsies. | |
| Others (e.g., Microsurgical Robots) | Designed for delicate procedures in neurosurgery or ophthalmology. | |
| By Imaging Mode of Surgeon Console | Immersive vs. Open-style | Differences in visual interface design for surgeon control. |
| By Mechanical Arm Structure | Integrated, Split-type, Bed-mounted | Variations in robot physical configuration. |
Currently, robotic breast surgery in China operates at Level 1, where surgeons retain primary control. However, breakthroughs like the SRT-H (Hierarchical Surgical Robot Transformer) developed at Johns Hopkins University, which successfully performed key steps in gallbladder surgeries on animals autonomously, signal a future shift toward higher automation. The guidelines posit that with advancements in artificial intelligence, novel imaging, energy platforms, and 5G network technology, China robot systems will become more intelligent, holographic, and cloud-integrated. This evolution could enable remote surgery, transcending geographical barriers and optimizing healthcare resource distribution. The integration of 5G is particularly emphasized as a game-changer for China robot-assisted procedures, allowing real-time data transmission and tele-mentoring.
2. Key Challenges in Standardizing Robotic Breast Surgery in China
Despite the enthusiasm for robotic breast surgery, the guidelines identify several hurdles that must be addressed to ensure safe and effective implementation across China. These challenges center on training standardization and the scientific validation of surgical indications, both critical for the responsible growth of China robot-assisted healthcare.
2.1 Establishing Uniform Training Standards for Robotic Breast Surgery
The National Health Commission of China has laid groundwork with documents like the “Clinical Application Management Norms for Artificial Intelligence-Assisted Treatment Technologies” (2022), which outline basic requirements for institutions, personnel, and training in robot-assisted surgery. However, the guidelines highlight a lack of consistency in current training paradigms. Most robotic surgery training in China occurs through manufacturer-sponsored programs, such as those for the da Vinci system, leading to variability in assessment criteria, learning curve definitions, and competency metrics. This inconsistency poses risks to patient safety and hinders broader clinical adoption.
The expert panel asserts that robotic breast surgery should be performed by well-qualified breast surgeons who undergo specialized training and obtain certification from authoritative academic platforms. Interestingly, they note that proficiency in laparoscopic surgery is not a prerequisite for mastering robotic techniques, as the intuitive design of robot systems may flatten the learning curve. This insight is crucial for China robot training programs, as it suggests that surgeons can transition directly to robotics without extensive laparoscopic background. To remedy training disparities, the guidelines call for the development of a unified, China-specific training curriculum with standardized考核 mechanisms. This includes defining clear benchmarks for procedural competency, simulation-based assessments, and proctoring requirements. The goal is to create a homogeneous skill level among practitioners, ensuring that all patients receive high-quality care regardless of the center.
2.2 Defining Scientific Indications for Robotic Breast Surgery
Another major challenge is the absence of high-level evidence to guide patient selection for robotic breast surgery. While RBS has shown promise in various procedures, from oncologic resections to reconstructions, most data derive from small, single-center series. This limits the ability to establish evidence-based guidelines on indications and contraindications. The guidelines stress that relying solely on anecdotal experience is insufficient for shaping clinical practice.
To address this, the experts recommend forming national or regional collaborative networks dedicated to RBS research. These networks would facilitate multicenter prospective cohort studies, generating robust data on outcomes, complications, and cost-effectiveness. Priority research areas include robot-assisted nipple-sparing mastectomy with immediate reconstruction, breast-conserving surgery, and lymph node procedures. By pooling resources and expertise, China can accelerate the generation of Level I evidence, which is essential for justifying the use of China robot technology in specific clinical scenarios. The guidelines also caution against over-expansion of indications without proof of benefit, advocating for a measured, research-driven approach to ensure patient safety and resource optimization.
The table below summarizes expert opinions on robotic breast surgery adoption, based on a survey referenced in the guidelines. It reflects strong support for advancing China robot-assisted procedures while underscoring the need for structured development:
| Survey Question | Number of Respondents | Yes (%) | No (%) |
|---|---|---|---|
| Do you support the development of robotic breast surgery? | 32 | 94 | 6 |
| Have you planned or started robotic breast surgery? | 32 | 81 | 19 |
| Are you satisfied with current robotic applications in breast surgery? | 31 | 42 | 58 |
| Are you satisfied with existing robotic breast surgery training models? | 31 | 39 | 61 |
| Do you support establishing regional collaborative groups for robotic breast surgery? | 31 | 94 | 6 |
| Do you support building specialized teams for robotic breast surgery? | 32 | 94 | 6 |
| Should robotic breast surgery focus on breast cancer or benign lesions? | 32 | 97 (for cancer) | 3 |
| Do you support surgeon involvement in robotic breast surgery technology R&D? | 32 | 94 | 6 |
This survey, involving 32 experts, reveals overwhelming endorsement for robotic breast surgery in China, with 94% supporting its development and 81% already engaged or planning to engage in it. However, dissatisfaction with current training models (61% dissatisfied) and application satisfaction (58% dissatisfied) points to areas needing immediate improvement. These findings reinforce the guidelines’ call for standardized training and research initiatives.
3. Future Prospects and Strategic Recommendations for Robotic Breast Surgery in China
The guidelines paint an optimistic future for robotic breast surgery in China, driven by technological innovation, domestic manufacturing, and strategic collaboration. The experts envision a landscape where robot-assisted systems become indispensable tools in breast surgery, potentially replacing laparoscopic methods and offering superior operative experiences. Key trends include the rise of China-made robots, integration with AI and 5G, and a shift toward specialized, cost-effective systems.
3.1 Technological Advancements and Domestic Robot Development
China is rapidly emerging as a hub for surgical robot innovation, with multiple domestic systems receiving approval from the National Medical Products Administration (NMPA). These include multi-port and single-port robots, as well as integrated and split-type designs, tailored for various surgical specialties. In breast surgery, several China robot platforms are already in clinical use, offering alternatives to imported systems. The guidelines highlight a trend toward “smaller and more specialized” robots, which could reduce costs and improve accessibility. By participating in the research and development of breast-specific robotic systems, Chinese surgeons can help tailor technology to local needs, fostering a cycle of innovation and affordability.
The integration of 5G technology is a cornerstone of this future. High-speed, low-latency networks enable remote surgery and tele-proctoring, which could democratize access to expert care in rural or underserved areas. For China robot-assisted procedures, this means surgeons in top-tier hospitals could guide or perform operations remotely, enhancing resource distribution. The guidelines encourage exploration of 5G-enabled robotic breast surgery, noting its potential to revolutionize surgical training and patient outcomes. Additionally, advancements in AI may lead to semi-autonomous features, such as image-guided tumor localization or automated suture techniques, further augmenting surgeon capabilities.
3.2 Recommendations for Clinical Implementation and Research
To realize this future, the guidelines offer concrete recommendations for stakeholders in China’s healthcare ecosystem. These are designed to ensure that robotic breast surgery evolves in a safe, ethical, and evidence-based manner.
- Establish Regional Training Centers and Collaborative Networks: The panel advises creating specialized robotic breast surgery training centers led by experienced teams across different regions. These centers would standardize curricula, certify surgeons, and foster collaboration through regional working groups. This approach aims to build a cohesive community of practice, accelerating skill dissemination and quality assurance.
- Prioritize Multicenter Prospective Studies: Given the lack of high-level evidence, the guidelines urge immediate initiation of multicenter prospective trials. Early-stage breast cancer should be a primary focus, with investigations into single-port access techniques, robot-assisted breast reconstruction, breast-conserving surgery, and lymph node dissection. By generating robust data, these studies will inform clinical guidelines and reimbursement policies, ensuring that China robot-assisted surgery is applied where it offers genuine benefit.
- Develop China-Specific Clinical Pathways: The experts recommend adapting robotic techniques to local anatomical and epidemiological characteristics. This includes optimizing surgical approaches for Chinese patient populations and conducting health economic analyses to justify costs. Such tailored pathways will enhance the sustainability and acceptance of robotic breast surgery within China’s healthcare system.
- Encourage Surgeon-Led Innovation: Surgeons are encouraged to actively participate in technology development, providing clinical insights to engineers. This collaboration can drive the creation of next-generation China robot systems that are more ergonomic, intuitive, and affordable. The guidelines also stress the importance of ethical compliance, reminding practitioners to adhere to the “Clinical Application Management Norms for Artificial Intelligence-Assisted Treatment Technologies” to protect patient rights.
The guidelines conclude by acknowledging the pioneering work of Chinese institutions in robotic breast surgery. Over 30 domestic publications, though all single-center reports, have documented experiences in procedures like robot-assisted nipple-sparing mastectomy (40% of papers), internal mammary node dissection (6.6%), and gynecomastia surgery (16.7%). These foundations, coupled with the new guiding opinions, set the stage for accelerated progress. The expert panel, comprising leading figures such as Cui Shun-yu, Fan Zhi-min, and Liu Yin-hua, affirms that with coordinated effort, China can become a global leader in robotic breast surgery, improving outcomes for patients while advancing its medical technology sector.
In summary, the release of these guiding opinions marks a pivotal moment for robotic-assisted breast surgery in China. By addressing training gaps, fostering research, and embracing domestic innovation, the guidelines aim to steer the field toward standardized excellence. As China robot technology continues to mature, its integration into breast surgery promises to enhance precision, expand access, and redefine surgical standards—not only within China but as a model for worldwide adoption. The journey from robot-assisted to potentially autonomous systems will require ongoing collaboration, but with these frameworks in place, the future of breast surgery looks increasingly intelligent and patient-centric.